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Background: Pharmacokinetic estimates for intravenous paracetamol in individual adult cohorts are different to a
certain extent, and understanding the covariates of these differences may guide dose individualization. In order to
assess covariate effects of intravenous paracetamol disposition in adults, pharmacokinetic data on discrete studies
were pooled.
Methods: This pooled analysis was based on 7 studies, resulting in 2755 time-concentration observations in 189
adults (mean age 46 SD 23 years; weight 73 SD 13 kg) given intravenous paracetamol. The effects of size, age,
pregnancy and other clinical settings (intensive care, high dependency, orthopaedic or abdominal surgery) on
clearance and volume of distribution were explored using non-linear mixed effects models.
Results: Paracetamol disposition was best described using normal fat mass (NFM) with allometric scaling as a
size descriptor. A three-compartment linear disposition model revealed that the population parameter estimates
(between subject variability,%) were central volume (V1) 24.6 (55.5%) L/70 kg with peripheral volumes of
distribution V2 23.1 (49.6%) L/70 kg and V3 30.6 (78.9%) L/70 kg. Clearance (CL) was 16.7 (24.6%) L/h/70 kg
and inter-compartment clearances were Q2 67.3 (25.7%) L/h/70 kg and Q3 2.04 (71.3%) L/h/70 kg. Clearance
and V2 decreased only slightly with age. Sex differences in clearance were minor and of no significance.
Clearance, relative to median values, was increased during pregnancy (FPREG = 1.14) and decreased during abdominal
surgery (FABDCL = 0.715). Patients undergoing orthopaedic surgery had a reduced V2 (FORTHOV = 0.649), while those in
intensive care had increased V2 (FICV = 1.51).
Conclusions: Size and age are important covariates for paracetamol pharmacokinetics explaining approximately 40%
of clearance and V2 variability. Dose individualization in adult subpopulations would achieve little benefit in the
scenarios explored.Background
Paracetamol (acetaminophen) is the most commonly
used drug to treat fever or pain, both as an over the
counter drug as well as in the hospital setting [1]. Para-
cetamol can be administered either in monotherapy or
as part of a multimodal approach, resulting in more
effective temperature control when combined with non-
steroidal anti-inflammatory drugs (NSAIDS) or equivalent
analgesia with lower opioid exposure [2-4]. In healthy* Correspondence: karel.allegaert@uzleuven.be
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unless otherwise stated.adults and using on label doses, paracetamol is almost
exclusively eliminated by conjugation into either para-
cetamol glucuronide (47 - 62%) or paracetamol sulphate
(25 - 36%), while limited amounts (1 - 4%) are excreted
in the urine as unchanged paracetamol or undergo
(<10%) oxidation to result in toxic metabolites (N-acetyl-
p-benzoquinone, NAPQI) [5,6]. At higher doses, or in
specific settings like alcohol abuse or malnutrition, the
oxidative pathway may be more active and may result in
hepatic necrosis [7]. When used in therapeutic dosages,
paracetamol is generally regarded as safe and well toler-
ated in a variety of patients.
While oral and rectal formulations have been popular for
the past century, an intravenous formulation has recently
been introduced into clinical care. Such an intravenousal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ative period if the oral route cannot yet be used, while
avoiding the unpredictability of absorption and bioavail-
ability following rectal administration. The development of
intravenous formulations has allowed time-concentration
profile observations unencumbered by absorption variabil-
ity. In addition to observations in healthy volunteers [8,9],
the pharmacokinetics in special populations have been
reassessed, including geriatric patients, abdominal surgery
cases, intensive care patients and women at delivery or in
postpartum [10-13].
Pooling of such datasets has the potential to further
explore covariates, including weight, gender or disease
characteristics [14-16]. Such an effort is of relevance.
This is because a unique and single dosing regimen in
any adult (i.e. 1 g intravenous paracetamol, q6h for max-
imal 48 hours) irrespective of other covariates may be an
over-simplification, omitting clinical settings with either
higher (insufficient effect) or lower clearance (raised risk
for toxicity). Information on covariates of intravenous
paracetamol disposition may be extrapolated to other
routes of administration, or even to other compounds
that undergo similar routes of elimination [5,17-19]. The
current pooled intravenous paracetamol PK study ex-
plores the impact of covariates (e.g. age, weight, preg-
nancy, intensive care, type of surgery) on paracetamol
disposition when compared to similar observations in
healthy adult volunteers.
Methods
Clinical observations
Observations of intravenous paracetamol disposition in
different cohorts of adults published in the literature
were pooled to explore covariate influences (e.g., gender,
age, size, disease characteristics, surgical procedure).
Cohorts were retrieved using a PubMed search that
included the ‘snowball method’, followed by an invita-
tion to the corresponding authors to provide the raw
data (time concentration profiles, clinical characteristics)
within a setting of academic collaboration [20]. Patient
demographics and age distribution are presented in Table 1
and Figure 1 respectively.
Healthy volunteer studies
Twelve healthy male volunteers (21–25 year, 63–83 kg)
were given a single dose of intravenous (IV) propaceta-
mol (1 g, equal to 0.5 g of paracetamol, Pro-Dalfagan,
Bristol-Myers Squibb Pharmaceuticals, Braine l′Alleud,
Belgium) and 13 blood samples for assay were subse-
quently collected for up to 24 h afterwards [8]. Paraceta-
mol concentrations were quantified in plasma by reverse
High Pressure Liquid Chromatography (HPLC) with UV
detection. The lower limit of quantification was 0.1 μg/ml.
Intra-assay coefficients of variation (CV) at 0.04, 1.25 and5 μg/ml were 6.4, 1.9 and 2% respectively, inter-assay CV
at 0.5 and 10 μg/ml were 3.3 and 2.2% respectively.
Healthy male (n = 12) and female (n = 14) volunteers
(19–34 year, 49–94 kg) were given IV paracetamol (2 g
loading dose, followed 1 g intravenous paracetamol 6
hourly, Perfalgan, Bristol Myers Squibb, Paris, France)
[9]. Plasma samples (n = 32) were collected for up to
48 h after the loading dose were collected, with specific
emphasis after the first and after the final 5th paracetamol
dose (at 24 h). All female volunteers were on contracep-
tives during the study, 13/14 based on oral contraceptives.
Paracetamol concentrations were quantified in plasma by
reverse HPLC with UV detection. The lower limit of
quantification was 0.02 μg/ml. Imprecision and inaccuracy
were lower than 3% and within 1% respectively.
Eight healthy female volunteers (27–37 year, 54–74 kg)
were studied following a single loading dose (2 g IV para-
cetamol, Perfalgan, Bristol Myers Squibb, Braine l′Alleud,
Belgium or intravenous Paracetamol, Fresenius Kabi,
Schelle, Belgium) (1,2,4,6 h) as part of a research project
concerning intravenous paracetamol disposition in preg-
nancy and postpartum [11]. None of these volunteers
were on oral contraceptives. Paracetamol concentrations
were quantified in plasma by reverse HPLC with UV de-
tection. The lower limit of quantification was 0.08 μg/ml.
Coefficients of variation for intra- and inter-day precision
and accuracy were all below 15%.
Clinical cohorts
Single dose IV paracetamol (1 g, Perfalgan 10 mg/L solu-
tion, Bristol-Myers Squibb, Agen, France) pharmacokinetics
have been documented in 40 patients following orthopaedic
surgery, with a study design to explore the age related
impact (20–88 year, 58–107 kg, male/female = 19/21) [10].
Plasma samples (n = 20) were collected in each patient for
up to 24 h. Paracetamol plasma concentrations were quan-
tified in plasma by HPLC. The lower limit of quantification
was 0.25 μg/ml. The interday CV for paracetamol was 12.8,
12.5 and 5.1% at 0.398, 2.01 and 10.1 μg/ml respectively.
As part of a study on IV paracetamol tolerance during
repeated administration in adults admitted in medium
(high dependency) and intensive care, paracetamol con-
centrations were quantified in 38 medium and intensive
care patients (34–82 year, 53–120 kg, male/female = 27/11)
after the first administration (1 g, Perfalgan, Bristol-Myers
Squibb BV, Woerden, The Netherlands) [12]. Blood sam-
ples were collected up to 6 h after initiation of intra-
venous administration with a ‘trough’ concentration
recorded before the second administration. Paraceta-
mol serum concentrations were quantified with fluor-
escent polarization immunoassay (Cobas Integra 400,
Roche Diagnostics, West Sussex, UK). Lower limit of
detection of the analysis was 0.2 μg/ml. Within-run
variation and total variation for low as well as high
Table 1 Summary data of the pooled studies
Reference ref 8 ref 9 ref 11 ref 10 ref 12 ref 13 ref 11 ref 11 Ref 11
Characteristics 12 healthy
males
12 healthy males 8 healthy
females
Orthopaedic
surgery
High dependency
and IC, 38 cases
Abdominal
surgery
Caesarean delivery Postpartum early Postpartum late,
14 healthy females 40 cases 20 cases 41 cases 8 cases (15 weeks) 7 cases (1 year)
Study design Single iv
bolus, 0.5 g
iv loading dose 2 g, single iv
bolus, 2 g
Single iv
bolus, 1 g
Single iv bolus, 1 g repeated
1 g, 6 qh
iv loading
dose 2 g,
maintenance
1 g q6h
iv loading 2 g iv loading 2 g
Maintenance 1 g q6h 48–72 h
Weight 63-83 kg 49-94 kg 54-74 kg 58-107 kg 53-120 kg 57-101 kg 57-110 kg 52-88 kg 50-87 kg
Age 21-25 years 19-34 years 27-37 years 20-88 years 34-82 years 44-85 years 31, SD 5.8 years 31, SD 5.8 years 32, SD 6 years
Sampling
strategy
13 samples/case 32 samples/case 4 samples/case 20 samples/case 8 samples/case 2x9 samples/case 4 samples after
loading dose + up
to 24 h
4 samples/case 4 samples/case,
up to 24 h up to 48 h up to 6 h up to 24 h up to 6 h up to 72 h up to 6 h up to 6 h
Analytical
technique
HPLC-uv HPLC-uv HPLC-uv HPLC Fluorescent
polarization
immuno-assay
HPLC HPLC-uv HPLC-uv HPLC-uv
LLOQ < 0.1 μg/ml < 0.02 μg/ml < 0.08 μg/ml < 0.25 μg/ml < 0.2 μg/ml n.a. < 0.08 μg/ml < 0.08 μg/ml < 0.08 μg/ml
CV% <6.4% < 3% < 15% < 12.8% < 7.5% n.a. < 15% < 15% < 15%
[IC = intensive care; iv = intravenous; SD = standard deviation, HPLC = High Pressure Liquid Chromatography; LLQ = lower limit of quantification; CV = coefficients of variation].
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Figure 1 Age distribution of included adults (volunteers or patients).
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a range of 0.7-5.8% and 4.4-7.5% respectively.
Twenty patients received IV paracetamol (1 g, 6 hourly,
up to 48–72 h, Perfalgan Bristol-Myers Squibb Ltd,
Auckland, New Zealand) after major abdominal surgery
(44–85 year, 57–101 kg, male/female = 8/12) [13]. Plasma
samples were collected over 2 intervals (day of surgery
and 2–3 days afterwards). Paracetamol concentrations
were quantified by HPLC.
Repeated dose IV paracetamol pharmacokinetics (load-
ing dose 2 g, followed by 1 g 6 hourly for 24 h) were col-
lected in a cohort of 41 women undergoing caesarean
delivery [11]. A subgroup of 8/41 women initially included
at delivery were recruited for a second single loading dose
(2 g paracetamol) PK study 10–15 weeks after delivery
and 7/8 women were re-evaluated a third time (single
loading dose, 2 g) about one year after delivery [11]. Blood
samples were collected after the loading dose (1, 2, 4 h)
with subsequent collection at trough (6, 12, 18 and 24 h).
More recently, 8 additional observations in women under-
going caesarean delivery were collected, resulting in 49
observations at delivery. Paracetamol plasma concentra-
tions were determined by HPLC. The lower limit of quan-
tification was 0.08 μg/ml. Coefficients of variation for
intra- and inter-day precision and accuracy were all below
15%.
Pharmacokinetic analysis
Population parameter estimates were obtained using non-
linear mixed effects modeling (NONMEM 7.3, Globomax
LLC, Hanover, MD, USA). This software accounts for
population parameter variability (between subjects) and
residual variability (random effects) as well as parameter dif-
ferences predicted by covariates (fixed effects). The popula-
tion parameter variability (or between subject variability,BSV) for structural model parameters were assumed to be
log-normally distributed across the population.
CLi ¼ TVCL⋅eηCLbsvþηCLbov
Vi ¼ TVVeηVbsvþηVboc
ηCLbsv is the difference between individual (CLi) and
population mean (TVCL), ηCLbov is the difference in
CL between occasions. ηVbsv is the difference between
individual (Vi) and population mean (TVV), and ηVbov
is the difference in V between occasions.
Residual unexplained variability (RUV) was modelled
using additive and proportional terms. The variance of
the RUV (ηRUV,i) was also estimated.
Ci ¼ F eCVCP þ SDCP
Ci is to concentration in the individual, F is the model
predicted concentration, CVCP is the coefficient of vari-
ation for the proportional error, and SDCP is the stand-
ard deviation of the additive error. Data from each assay
laboratory was assigned individual.
The first order conditional interaction estimate method
using ADVAN3 TRAN4 was used to estimate population
mean parameters, between subject variance and residual
variance. Convergence criterion was 3 significant digits.
Initial analyses suggested a three-compartment dispos-
ition model for paracetamol and the model was parame-
terized in terms of clearance (CL), inter-compartment
clearances (Q2, Q3), central volume (V1) and peripheral
volumes (V2, V3). The population parameter variability
was modelled in terms of random effect (η) variables.
Each of these variables was assumed to have mean 0 and
a variance denoted by ω2, which was estimated. The co-
variance between two elements of η (e.g. CL and V) is a
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ables. Their covariance is related to their correlation (R)
i.e.
R ¼ covariance=✓ w2CL x w2V
 
The covariance of parameter variability was incorpo-
rated into the model.
Covariate analyses
a) Size
We investigated three measures of body size
Total body weight (TBW) (kg)
Fat Free Mass (FFM)
Fat free mass (FFM) can be predicted from TBW and
height (H, m) [21].
FFM ¼ WHSmax⋅H2⋅ TBW= WHS50⋅H2 þ TBW
  
where WHSmax is the maximum FFM for any given
height (H, m) and WHS50 is the TBW value when FFM
is half of WHSmax. For men, WHSmax is 42.92 kg/m
2
and WHS50 is 30.93 kg/m
2 and for women WHSmax is
37.99 kg/m2 and WHS50 is 35.98 kg/m
2.
normal fat mass (NFM)
Normal fat mass (NFM) is an extension of the concept
of predicted normal weight [22] with a parameter (Ffat)
which accounts for different contributions of fat mass
(i.e. TBW minus FFM)
NFM kgð Þ ¼ FFMþFfat⋅ TBW−FFMð Þ
Instead of assuming a fixed value of Ffat in all cases
the idea of NFM is to estimate the value of Ffat that is
most appropriate for the parameter being predicted. If
Ffat is estimated to be zero then FFM alone is required
to predict size while if Ffat is 1 then size is predicted by
TBW. Other estimates of Ffat reflect different weighting
of body composition components.
The parameter values were standardised for a body
size using an allometric model [23,24].
Pi ¼ Pstd  Xi=Wstdð ÞPWR
where Pi is the parameter in the i
th individual, Xi is a
measure of body size (TBW, FFM or NFM) in the ith in-
dividual and Pstd is the parameter in an individual with a
standard size Wstd . The PWR exponent is 0.75 for clear-
ance and 1 for distribution volumes [25-27]. Thus totaldrug clearance may be expected to scale with a power of
¾ with the allometric model:
CLi ¼ CLstd  Xi=70ð Þ3=4
where CLstd is the population estimates for CL.
b) Age
The effect of age (years) on clearance or distribution
volumes was investigated using a scaling factor (FAGECL,
FAGEV). The majority of patients were either younger
than 40 years or older than 60 years (Figure 1). The for-
mula for FFM was based on adults aged up to 60 years.
Consequently if patients were aged above 60 years, then
a scaling factor (FAGE) was applied to CL or V popula-
tion estimates.
c) Sex
The male was taken as the standard and a scaling fac-
tor (FSEXCL) estimated if the patient was female:
CL ¼ FAGECL  FSIZECL  FSEXCL  CLstd
d) Other covariates
A similar approach, using a scaling factor was taken
with other covariates [pregnancy (FPREG), postpartum
(FPP), intensive care (FIC), high dependency care (FHD)
abdominal surgery (FABD) and orthopaedic surgery
(FORTHO)] and their impact on clearance or volume re-
spectively, e.g.
CL ¼ FAGECL  FSIZECL  FSEXCL  FPREG  FICCL
 FHDCL  FABDCL  CLstd
V2 ¼ FSIZEV2  FAGEV2  FORTHOV2  FICV2  V2std
Quality of fit
The quality of fit of the pharmacokinetic model to the
data was sought by NONMEM’s objective function and
by visual examination of plots of observed versus pre-
dicted concentrations. Models were nested and an im-
provement in the objective function was referred to the
Chi-squared distribution to assess significance e.g. an
objective function change (OBJ) of 3.84 is significant at
α = 0.05. An objective function change of 6.635 (p <
0.01) was used to determine covariate inclusion. Boot-
strap methods provided a means to evaluate parameter
uncertainty [28]. A total of 1000 replications were used
to estimate parameter confidence intervals. A visual pre-
dictive check (VPC) [29], a modeling tool that estimates
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superimposes these intervals on observed concentra-
tions after a standardized dose, was used to evaluate
how well the model predicted the distribution of ob-
served plasma concentrations. Simulation was performed
using 1000 subjects with characteristics taken from the
pooled population. For data such as these where covari-
ates such as dose, size, sex, age, or pathology are different
for each patient, we used a prediction corrected VPC (PC-
VPC) [30].
Simulation
A simulation study was performed to investigate both
concentration variability in a 25 year old 70 kg healthy
adult volunteer given a standard dose of intravenous
paracetamol 1 g 6 hourly for 36 h, and typical time-
concentration profiles in a 68 year old 70 kg male in in-
tensive care, a 25 year 70 kg pregnant woman in her
third trimester, the same woman 2 months postpartum
weighing 60 kg, and a 68 year old 70 kg male undergo-
ing abdominal surgery. The drug was infused over 15 mi-
nutes. Pharmacokinetic parameter estimates and their
variability from this current pooled study were used to
predict individual time-concentration profiles.Table 2 Key model building steps and associated objective fu
Basic model
1-compartment - no size scaling
2-compartment - no size scaling
3-compartment – no size scaling
3-compartment – no size scaling + individual study centre RUV
+BOV
+BOV + allometric scaling FFM
+BOV + allometric scaling TBW
+BOV + allometric scaling NFM
+BOV + allometric scaling NFM FfatCL = 1
+BOV + allometric scaling NFM FfatCL = 0
+BOV + allometric scaling NFM FfatCL = 1 + FAGEV
+BOV + allometric scaling NFM FfatCL = 1 + FAGEV + FAGECL
+BOV + allometric scaling NFM FfatCL = 1 + FAGEV + FAGECL + FSEXCL
+BOV + allometric scaling NFM FfatCL = 1 + FAGEV + FAGECL + FPREGCL
+BOV + allometric scaling NFM FfatCL = 1 + FAGEV + FAGECL + FPREGCL + FICCL
+BOV + allometric scaling NFM FfatCL = 1 + FAGEV + FAGECL + FPREGCL + FICVOL
+BOV + allometric scaling NFM FfatCL = 1 + FAGEV + FAGECL + FPREGCL + FICV + FH
+BOV + allometric scaling NFM FfatCL = 1 + FAGEV + FAGECL + FPREGCL + FICV + FO
+BOV + allometric scaling NFM FfatCL = 1 + FAGEV + FAGECL + FPREGCL + FICV + FO
+BOV + allometric scaling NFM FfatCL = 1 + FAGEV + FPREGCL + FICV + FORTHOV + F
An OBJ decrease of 6.635 (p < 0.01) for these nested models was deemed significan
[BOV = between occasion variability; RUV = residual unexplained variability; FFM = f
abd = abdominal surgery; preg = pregnant; IC = intensive care; HD = high dependenResults
The pooled analysis included 2755 paracetamol obser-
vations in 189 individuals. The clinical characteristics
and medical conditions of the individual studies were
already mentioned in the methods section, but the pooled
dataset of adults had a mean weight of 73 kg (range 49.2 –
120 kg) and age 46 years (range 19–88.5 year). The distri-
bution of ages was shown in Figure 1. All data were above
the lower limit of quantification reported from each of the
individual studies.
The model building process is shown in Table 2. A
three compartment disposition model was better than a
one or two-compartment model. Size scaling using NFM
and allometry reduced the objective function more than
either TBW or NFM. The estimate for FfatCL approached
1 (FfatCL = 0.989) and when this estimate was fixed at 1,
the objective function change was small. Fixing FfatCL to 0
increased the objective function (ΔOBJ 19.238). We had
concerns that pregnant women may require a further
“correction factor” but this turned out to be unnecessary
since there was no improvement in the objective function
when applied to either clearance or volume of distribu-
tion. Both clearance and the peripheral volume of distri-
bution V2 were reduced in the elderly, but when elderlynction changes
OBJ
8350.263
5804.790
5762.275
5210.072
5024.826
4956.866
4942.960
4927.983
4924.844
4946.221
4908.588
4901.989
4900.663
-FSEXCL 4893.125
4888.551
-FICCL 4876.427
DUCL 4875.677
RTHOV -FHDUCL 4839.712
RTHOV + FABDCL 4827.174
ABDCL -FAGECL 4827.284
t for covariate inclusion.
at free mass; TBW = total body weight; NFM = normal fat mass; CL = clearance;
cy care; ortho = orthopaedic surgery].
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for, this reduction was no longer apparent. Sex differences
in clearance were minor and of no significance. Clearance,
relative to the population median, was increased during
pregnancy (FPREG = 1.14), and decreased during abdom-
inal surgery (FABD =0.715). Clearance was not different in
postpartum women. Patients undergoing orthopaedic sur-
gery had a smaller V2 (FORTHO = 0.649) while those in in-
tensive care had an increased V2 (FICV = 1.51). Once these
covariate effects were established we were unable to deter-
mine any further effect attributable to sex. The final covar-
iates of value to describe clearance were allometry using
TBW, pregnancy and abdominal surgery
CL ¼ FSIZECL  FPREGCL  FABDCL  CLstd
The final covariates of value to describe V2 were al-
lometry using NFM, age, orthopaedic surgery and inten-
sive care.
V2 ¼ FSIZEV2  FAGEV2  FORTHOV2  FICV2  V2std
Parameter estimates for the final model are shown in
Table 3. Residual unexplained additive and proportional
errors for all 5 study sites were similar except for the
additive error for the study investigating elderly ortho-
paedic patients (the centre for that study reported the
highest lower limit of quantification). The residual additive
errors were 0.09, 0.03, 1.1, 0.07, 0.02 mg/L for each centre.
The proportional errors were 0.09, 0.06, 0.04, 0.09, 0.15
for the same centres with a ηRUV,i of 0.231. The correlationTable 3 Standardised intravenous paracetamol
population pharmacokinetic parameter estimates
Parameter Estimate BSV BOV 95% CI
CLstd (L.h−1.70 kg−1) 16.7 0.246 0.231 15.2, 17.8
FPREGCL 1.14 - - 1.02, 1.27
FfatCL 1 FIX - - -
FABDCL 0.715 - - 0.548, 0.832
V1std (L.70 kg−1) 24.6 0.555 - 21.7, 27.1
Q2std (L.h−1.70 kg−1) 67.3 0.257 - 56.1, 79.7
V2std ( L.70 kg−1) 23.1 0.496 0.051 20.2, 26.1
FfatVOL 0.778 - - 0.503, 0.933
FORTHOV2 0.649 - - 0.485, 0.876
FICV2 1.51 - - 1.07, 2.90
FageV2 0.838 - - 0.702, 0.968
Q3 2.04 0.713 - 1.69, 2.81
V3 30.6 0.789 - 20.4, 64.3
(BSV is the between subject variability, CLstd = standardized clearance; preg =
pregnancy; IC = intensive care; abd = abdominal surgery; ortho = orthopaedic
surgery; BOV = between occasion variability; CI = confidence interval).of between subject variability for structural parameters is
shown in Table 4.
Between occasion variability for clearance and V2 were
0.231 and 0.051 respectively. The between-subject vari-
ability (BSV) for clearance and V2 without covariates in
the model were 0.436 and 0.666 respectively. This differ-
ence between BSV without covariates and with covari-
ates is a measure of the predictable decrease in BSV due
to covariates. The ω2 estimates for the different compo-
nents contributing to variability of CL and V2 are shown
in Tables 5 and 6 respectively. The ratio of the population
parameter variability (PPVP2) predictable from covariates
(BSVR2 + BOV2) to the total population parameter vari-
ability obtained without covariate analysis (PPVt2) gives
an indication about how important covariate informa-
tion is. For example, the ratio of 0.401 achieved for clear-
ance in this current study indicates that 40.1% of the
overall variability in clearance is predictable from covari-
ate information.
PC-VPC plots, used to demonstrate goodness of fit,
are shown in Figure 2. Typical time-concentration pro-
files from the simulation study are shown in Figure 3.
The mean concentration in patients with all types of
pathology was 11.6 SD 1.9 mg/L. There is little differ-
ence in profiles due to the differences in pathology in
this pooled analysis.
Discussion
Pooling of data allowed confirmation of the extent of the
different covariates explored in individual studies and also
provided new information about size scaling approaches.
After allometric scaling and size standardization, preg-
nancy, and abdominal surgery, but not gender were signifi-
cant covariates of clearance, explaining 40% of clearance
variability. Age, intensive care and orthopaedic surgery in
part (38%) explained the variability in distribution.
The paracetamol pharmacokinetic parameter estimates
were the same as those predicted from paediatric data
scaled using allometry with TBW [14]. Mature clearance,
achieved within the first few years of life was 16.2 L/h/
70 kg (BSV 0.45, BOV 23.5) and Vss was 63.2 L/70 kg.
However, the best descriptor of size may not necessarilyTable 4 The correlation of parameter between-subject
variability
CL V2 V1 Q2 Q3 V3
CL 1
V2 0.060 1
V1 0.265 −0.734 1
Q2 0.254 0.793 −0.170 1
Q3 0.956 −0.134 0.432 0.136 1
V3 0.379 −0.818 0.530 −0.750 0.544 1
[CL = clearance; V = distribution volume: Q = intercompartemental clearance].
Table 5 Effect of covariate analysis on variance (ω2) of Clearance
Sequential nested model PPVt2 BSVR2 BOV2 PPVP2 PPVP2/PPVt2
No covariates 0.19 0.19 0 0 0
Allometric scaling (TBW) 0.19* 0.10 0.0413 0.0487 0.256
Allometric scaling (NFM) 0.19* 0.0889 0.0557 0.0454 0.239
FAGECL 0.19* 0.0799 0.0557 0.0544 0.286
FPREGCL 0.19* 0.0803 0.0513 0.0584 0.3074
FABDCL 0.19* 0.0605 0.0533 0.0762 0.401
* = assumed from no covariate model estimate.
[PPV = population parameter variability; BSV = between subject variability; BOV = between occasion variability; TBW = total body weight; NFM = normal fat mass;
preg = pregnant, abd = abdominal surgery; IC = intensive care patients; ortho = orthopaedic surgery].
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drug. Lean body mass (LBM) is appropriate for remifen-
tanil, while propofol clearance in obese adults and non-
obese adults and children is best predicted using TBW
as the size descriptor with theory based allometry
[31-34]. Paracetamol appears best described using nor-
mal fat mass (NFM) with allometric scaling as a size de-
scriptor. This approach is versatile [34] because in
addition to FFM (FFM is similar to LBW but excludes
lipids in cell membranes and for all practical purposes
these two descriptors are indistinguishable) there is an
additional parameter, Ffat that characterizes the contri-
bution of fat mass (TBW-FFM) to the apparent allomet-
ric size of the body. This parameter is drug specific (it
depends on the physico-chemical characteristics of the
compound) and also specific to the PK parameter such
as clearance or volume of distribution [35].
A review of paracetamol pharmacokinetics as reported
in literature [17,18,36-44] suggests that clearance de-
creases by 0.4%/year and volume of distribution de-
creases by 0.3%/year (using the young, 25 year old as the
standard). This is equivalent to 20% decrease in CL and
15% decrease in volume of distribution from age 25 to
age 75. The age distribution in this current study did not
facilitate the use of a linear or exponential function to
investigate this change. Although we noted a 12% de-
crease in V2 in the elderly, the contribution that age
made to clearance was overshadowed by the reduced
clearance noted in the elderly cohort who had abdom-
inal surgery. These patients comprised an older cohortTable 6 Effect of covariate analysis on variance (ω2) of V2
Sequential Nested Model PPVt2 BSVR2
No covariates 0.437 0.437
Allometric scaling (TBW) 0.437* 0.396
Allometric scaling (NFM) 0.437* 0.348
FAGEV2 0.437* 0.304
FICV2 0.437* 0.299
FORTHOV2 0.437* 0.246
* = assumed from no covariate model estimate.(age 67, range 49–85 years), and the severity of illness or
frailty may have further contributed to reduced clear-
ance. Wynne reports a further large decrease (36%) in
clearance in frail elderly compared to healthy elderly
[44]. A similar explanation may apply to the elderly co-
hort undergoing orthopaedic surgery who had a reduced
volume of distribution. Volume changes probably reflect
increased fat per kilogram body weight in the elderly,
together with incomplete distribution of this non-
lipophilic drug into body fat. Increased paracetamol clear-
ance was observed during late trimester pregnancy, even
after size scaling.
Others have reported an apparent oral clearance 58%
higher in pregnant women compared to non-pregnant
women [45,46]. After allowing for allometry and size
models, we report a smaller increase in clearance than
this estimate. The higher clearance in pregnant women
(FPREGCL = 1.14) is due to a higher than proportional in-
crease in glucuronidation, a proportional increase in oxi-
dation and a subproportional increase in primary renal
elimination [11]. Potentially hepatotoxic metabolites
were not quantified in the maternal serum [11,46]. This
increased clearance was no longer present 2–3 months
after delivery when clearance was indistinguishable from
the population mean [11].
There are data suggesting that women taking steroid
oral contraceptives have increased glucuronidation of
paracetamol of up to 50% and the impact of both preg-
nancy and oral contraceptives on intravenous paracetamol
disposition [47,48]. Has recently been confirmed and mayBOV2 PPVP2 PPVP2/PPVt2
0 0 0
0.00297 0.03803 0.087025
0.00325 0.08575 0.196224
0.00272 0.13028 0.298124
0.00222 0.13578 0.310709
0.0258 0.1652 0.378032
Figure 2 Visual predictive check for the paracetamol 2-compartment model. All plots show median and 90% intervals (solid and dashed
lines). Left hand plot shows all observed concentrations. Right hand plot shows prediction percentiles (10%, 50%, and 90%) for observations (lines
with symbols) and predictions (lines) with 95% confidence intervals for prediction percentiles (gray shaded areas).
Allegaert et al. BMC Anesthesiology 2014, 14:77 Page 9 of 11
http://www.biomedcentral.com/1471-2253/14/77be driven by oestradiol [49]. In the current pooled ana-
lysis, we were unable to show that sex was a covariate.
Figure 2 demonstrates to what extent these patient re-
lated covariates affect the time-concentration profiles
when compared to a reference 25 year old healthy volun-
teer. Predictions for healthy volunteer are not different
from plots of typical individual with pathology. The mean
concentration of 11.6 mg/L across all groups is consistent
with the assumed target concentration of 10 mg/L associ-
ated with pain reduction of pain reduction of 2.6/10 [50].
Little is known about pharmacodynamic covariate effects
in adults. Despite identification of pharmacokinetic covar-
iate influences, the unexplained parameter variability still
remains high (60% for CL) and dose individualization
or subpopulation ‘tailored’ dosing would achieve littleFigure 3 Time-concentration profiles for a 25 year old 70 kg healthy ad
1 g 6 hourly and typical time-concentration profiles a 25 year 70 kg pre
undergoing abdominal surgery.benefit in the scenarios observed. Target concentration
intervention would be of little value. It is of use if a re-
sponse, such as blood pressure, is substitute for measuring
the clinical disease state that is being treated. When the
medicine is working well or it is not working at all the
clinical disease state may appear to be the same. It is as-
sumed that trying to reach a typical response that is usu-
ally associated with benefit is better than giving everyone
the same dose. The second reason for using target con-
centration intervention is when group based dosing (e.g.
using weight) is not enough to reduce the between subject
variability so that the medicine can be used safely and ef-
fectively. Target concentration intervention can only work
however if the within subject variability is small enough so
that dose individualization is really predictive for futureult volunteer given a standard dose of intravenous paracetamol
gnant woman in her third trimester and a 68 year old 70 kg male
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http://www.biomedcentral.com/1471-2253/14/77use of the medicine in the same patient. The clearance co-
variate analysis on variance (ω2) only accounts for 40% of
the between subject variability for paracetamol.
Aside from the absence of additional benefit, there may
also be a higher risk of developing hepatotoxicity when
dose is increased beyond 4 g per day. At least, there are
conflicting reports on the association of raised amino-
transferase concentrations (>3 times upper limits of nor-
mal) in healthy adults receiving paracetamol [9,51,52].
Conclusions
Size and age are important covariates for paracetamol
pharmacokinetics, with additional impact of clinical pa-
tient characteristics like pregnancy, abdominal and ortho-
paedic surgery. However, dose individualization based on
these covariates would achieve little clinical benefit in the
scenarios explored. Since changes in overall paracetamol
clearance do not necessary result in proportional changes
of the different metabolic elimination routes, further stud-
ies on paracetamol metabolism in these specific popula-
tions are warranted to identify populations at risk.
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